Review: Impact of Helicobacter pylori on Alzheimer's disease: What do we know so far?

Helicobacter

Volumn 23, Issue 1, 2018, Pages

  Doulberis, Michael ^a   Kotronis, Georgios ^b   Thomann, Robert ^a   Polyzos, Stergios A ^c   Boziki, Marina ^c   Gialamprinou, Dimitra ^c   Deretzi, Georgia ^c   Katsinelos, Panagiotis ^c   Kountouras, Jannis ^c  

^a Bürgerspital Hospital of Solothurn   (Switzerland)

^b Agios Pavlos General Hospital   (Macedonia)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Alzheimer's disease; cognitive impairment; dementia; gastric inflammation; Helicobacter pylori; tauopathy

Indexed keywords

ALZHEIMER DISEASE; AUTOPHAGY; BLOOD BRAIN BARRIER; DISEASE ASSOCIATION; DISEASE COURSE; ENGLISH (LANGUAGE); HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; ANIMAL; COMPLICATION; GASTROINTESTINAL TRACT; MICROBIOLOGY; OLFACTORY SYSTEM; PATHOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; GASTROINTESTINAL TRACT; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; OLFACTORY PATHWAYS;

EID: 85035219140     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12454     Document Type: Review

References (255)

1. Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153:420-429.
2. Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. Helicobacter. 2014;19(Suppl 1):1-5.
3. McKinnon SJ. Glaucoma: ocular Alzheimer's disease? Front Biosci. 2003;8:s1140-s1156.
4. Bourne RRA, Taylor HR, Flaxman SR, et al. Number of people blind or visually impaired by glaucoma worldwide and in world regions 1990-2010: a meta-analysis. PLoS ONE. 2016;11:e0162229.
5. Howard J, Trevick S, Younger DS. Epidemiology of multiple sclerosis. Neurol Clin. 2016;34:919-939.
6. Fiest KM, Roberts JI, Maxwell CJ, et al. The prevalence and incidence of dementia due to Alzheimer's disease: a systematic review and meta-analysis. Can J Neurol Sci. 2016;43(Suppl 1):S51-S82.
7. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet (London, England). 1984;1:1311-1315.
8. Watts G. Nobel prize is awarded to doctors who discovered H. pylori. BMJ. 2005;331:795.
9. Posselt G, Crabtree JE, Wessler S. Proteolysis in Helicobacter pylori-induced gastric cancer. Toxins (Basel). 2017;9:134.
10. Handa O, Naito Y, Yoshikawa T. Redox biology and gastric carcinogenesis: the role of Helicobacter pylori. Redox Rep. 2011;16:1-7.
11. Yang L, Pei Z. Bacteria, inflammation, and colon cancer. World J Gastroenterol. 2006;12:6741-6746.
12. Rook GAW, Brunet LR. Microbes, immunoregulation, and the gut. Gut. 2005;54:317-320.
13. Chow J, Tang H, Mazmanian SK. Pathobionts of the gastrointestinal microbiota and inflammatory disease. Curr Opin Immunol. 2011;23:473-480.
14. Rook GAW, Adams V, Hunt J, Palmer R, Martinelli R, Brunet LR. Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders. Springer Semin Immunopathol. 2004;25:237-255.
15. Housseau F, Sears CL. Enterotoxigenic Bacteroides fragilis (ETBF)-mediated colitis in Min (Apc+/-) mice: a human commensal-based murine model of colon carcinogenesis. Cell Cycle. 2010;9:3-5.
16. Nagamine CM, Rogers AB, Fox JG, Schauer DB. Helicobacter hepaticus promotes azoxymethane-initiated colon tumorigenesis in BALB/c-IL10-deficient mice. Int J Cancer. 2008;122:832-838.
17. Doulberis M, Angelopoulou K, Kaldrymidou E, et al. Cholera-toxin suppresses carcinogenesis in a mouse model of inflammation-driven sporadic colon cancer. Carcinogenesis. 2015;36:280-290.
18. Poutahidis T, Cappelle K, Levkovich T, et al. Pathogenic intestinal bacteria enhance prostate cancer development via systemic activation of immune cells in mice. PLoS ONE. 2013;8:e73933.
19. Wakabayashi A, Nakagawa Y, Shimizu M, Moriya K, Nishiyama Y, Takahashi H. Suppression of an already established tumor growing through activated mucosal CTLs induced by oral administration of tumor antigen with cholera toxin. J Immunol. 2008;180:4000-4010.
20. Kountouras J, Polyzos SA, Zavos C, et al. Helicobacter pylori might contribute to nonalcoholic fatty liver disease-related cardiovascular events by releasing prothrombotic and proinflammatory factors. Hepatology. 2014;60:1450-1451.
21. Kountouras J, Polyzos SA, Katsinelos P, et al. Cardio-cerebrovascular disease and Helicobacter pylori-related metabolic syndrome: We consider eradication therapy as a potential cardio-cerebrovascular prevention strategy. Int J Cardiol. 2017;229:17-18.
22. Kountouras J, Polyzos SA, Zeglinas C, et al. Helicobacter pylori-related metabolic syndrome as predictor of progression to esophageal carcinoma in a subpopulation-based Barrett's esophagus cohort. Gastrointest Endosc. 2017;85:462-463.
23. Kountouras J, Boziki M, Polyzos SA, et al. Impact of reactive oxygen species generation on Helicobacter pylori-related extragastric diseases: a hypothesis. Free Radic Res. 2017;51:73-79.
24. Kountouras J, Polyzos SA, Katsinelos P, et al. Helicobacter pylori on portal hypertension-related hepatic encephalopathy. Immunopharmacol Immunotoxicol. 2017;39:105-106.
25. Kountouras C, Polyzos SA, Stergiopoulos C, et al. A potential impact of Helicobacter pylori infection on both obstructive sleep apnea and atrial fibrillation-related stroke. Sleep Med. 2017;34:256.
26. Franceschi F, Gasbarrini A, Polyzos SA, Kountouras J. Extragastric diseases and Helicobacter pylori. Helicobacter. 2015;20(Suppl 1):40-46.
27. Franceschi F, Tortora A, Gasbarrini G, Gasbarrini A. Helicobacter pylori and Extragastric diseases. Helicobacter. 2014;19:52-58.
28. Wang X-L, Zeng J, Yang Y, et al. Helicobacter pylori filtrate induces Alzheimer-like tau hyperphosphorylation by activating glycogen synthase kinase-3β. J Alzheimers Dis. 2015;43:153-165.
29. Zeng J, Liu H, Liu X, Ding C. The relationship between Helicobacter pylori infection and open-angle glaucoma: a meta-analysis. Invest Ophthalmol Vis Sci. 2015;56:5238-5245.
30. Deretzi G, Gavalas E, Boziki M, et al. Impact of Helicobacter pylori on multiple sclerosis-related clinically isolated syndrome. Acta Neurol Scand. 2016;133:268-275.
31. Deretzi G, Kountouras J, Grigoriadis N, et al. From the “little brain” gastrointestinal infection to the “big brain” neuroinflammation: a proposed fast axonal transport pathway involved in multiple sclerosis. Med Hypotheses. 2009;73:781-787.
32. Franceschi F, Annalisa T, Teresa DR, et al. Role of Helicobacter pylori infection on nutrition and metabolism. World J Gastroenterol. 2014;20:12809-12817.
33. Kountouras J, Boziki M, Gavalas E, et al. Five-year survival after Helicobacter pylori eradication in Alzheimer disease patients. Cogn Behav Neurol. 2010;23:199-204.
34. Kountouras J, Boziki M, Gavalas E, et al. Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease. J Neurol. 2009;256:758-767.
35. Roubaud-Baudron C, Krolak-Salmon P, Quadrio I, Mégraud F, Salles N. Impact of chronic Helicobacter pylori infection on Alzheimer's disease: preliminary results. Neurobiol Aging. 2012;33:1009.e11-9.
36. Kountouras J, Gavalas E, Polyzos SA, et al. Association between Helicobacter pylori burden and Alzheimer's disease. Eur J Neurol. 2014;21:e100.
37. Tsolaki F, Kountouras J, Topouzis F, Tsolaki M. Helicobacter pylori infection, dementia and primary open-angle glaucoma: are they connected? BMC Ophthalmol. 2015;15:24.
38. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet. 2009;374:1196-1208.
39. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80:1778-1783.
40. Taylor CA, Greenlund SF, McGuire LC, Lu H, Croft JB. Deaths from Alzheimer's Disease - United States, 1999-2014. MMWR Morb Mortal Wkly Rep. 2017;66:521-526.
41. Grasset L, Brayne C, Joly P, et al. Trends in dementia incidence: Evolution over a 10-year period in France. Alzheimers Dement. 2016;12:272-280.
42. Schrijvers EMC, Verhaaren BFJ, Koudstaal PJ, Hofman A, Ikram MA, Breteler MMB. Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology. 2012;78:1456-1463.
43. Pérès K, Brayne C, Matharan F, et al. Trends in prevalence of dementia in French farmers from two epidemiological cohorts. J Am Geriatr Soc. 2017;65:415-420.
44. Matthews FE, Stephan BCM, Robinson L, et al. A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II. Nat Commun. 2016;7:11398.
45. Matthews FE, Arthur A, Barnes LE, et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet (London, England). 2013;382:1405-1412.
46. Cuccaro D, De Marco EV, Cittadella R, Cavallaro S. Copy number variants in Alzheimer's disease. J Alzheimers Dis. 2017;55:37-52.
47. Santos CY, Snyder PJ, Wu W-C, Zhang M, Echeverria A, Alber J. Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimer's Dement (Amsterdam, Netherlands). 2017;7:69-87.
48. Kountouras J, Zavos C, Boziki M, Gavalas E, Kyriakou P, Deretzi G. Association between Helicobacter pylori infection and Alzheimer's disease in Japan. J Neurol. 2011;258:2086.
49. Zavos C, Kountouras J, Deretzi G, et al. Hpn protein as a mediator between Helicobacter pylori infection and Alzheimer's disease in sub-populations worldwide. Med Hypotheses. 2012;78:349-350.
50. Kountouras J, Gavalas E, Zavos C, et al. Alzheimer's disease and Helicobacter pylori infection: Defective immune regulation and apoptosis as proposed common links. Med Hypotheses. 2007;68:378-388.
51. Bu X-L, Yao X-Q, Jiao S-S, et al. A study on the association between infectious burden and Alzheimer's disease. Eur J Neurol. 2015;22:1519-1525.
52. Kountouras J, Deretzi G, Gavalas E, et al. A proposed role of human defensins in Helicobacter pylori-related neurodegenerative disorders. Med Hypotheses. 2014;82:368-373.
53. Kountouras J, Boziki M, Gavalas E, et al. Increased cerebrospinal fluid Helicobacter pylori antibody in Alzheimer's disease. Int J Neurosci. 2009;119:765-777.
54. Honjo K, van Reekum R, Verhoeff NPLG. Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Alzheimers Dement. 2009;5:348-360.
55. Green C, Zhang S. Predicting the progression of Alzheimer's disease dementia: A multidomain health policy model. Alzheimers Dement. 2016;12:776-785.
56. Karantzoulis S, Galvin JE. Distinguishing Alzheimer's disease from other major forms of dementia. Expert Rev Neurother. 2011;11:1579-1591.
57. Wolfson C, Wolfson DB, Asgharian M, et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med. 2001;344:1111-1116.
58. Suh MK, Kim H, Na DL. Dysphagia in patients with dementia: Alzheimer versus vascular. Alzheimer Dis Assoc Disord. 2009;23:178-184.
59. Kountouras J, Boziki M, Zavos C, et al. A potential impact of chronic Helicobacter pylori infection on Alzheimer's disease pathobiology and course. Neurobiol Aging. 2012;33:e3-e4.
60. Ganguly G, Chakrabarti S, Chatterjee U, Saso L. Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer's disease and Parkinson's disease. Drug Des Devel Ther. 2017;11:797-810.
61. Reddy PH, Beal MF. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med. 2008;14:45-53.
62. Fessel J. Amyloid is essential but insufficient for Alzheimer causation: addition of subcellular cofactors is required for dementia. Int J Geriatr Psychiatry. 2017; https://doi.org/10.1002/gps.4730 [Epub ahead of print].
63. Jiang C, Li G, Huang P, Liu Z, Zhao B. The gut microbiota and Alzheimer's disease. J Alzheimers Dis. 2017;58:1-15.
64. Domingues C, da Cruz E Silva OAB, Henriques AG. Impact of cytokines and chemokines on Alzheimer's disease neuropathological hallmarks. Curr Alzheimer Res. 2017;14:870-882.
65. Mietelska-Porowska A, Wojda U. T lymphocytes and inflammatory mediators in the interplay between brain and blood in Alzheimer's disease: potential pools of new biomarkers. J Immunol Res. 2017;2017:4626540.
66. Sochocka M, Zwolińska K, Leszek J. The infectious etiology of Alzheimer's disease. Curr Neuropharmacol. 2017;15:996-1009.
67. Tian X, Cecal R, McLaurin J, et al. Identification and structural characterisation of carboxy-terminal polypeptides and antibody epitopes of Alzheimer's amyloid precursor protein using high-resolution mass spectrometry. Eur J Mass Spectrom (Chichester, Eng). 2005;11:547-556.
68. Aisen PS. The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors. CNS Drugs. 2005;19:989-996.
69. Blasko I, Grubeck-Loebenstein B. Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease. Drugs Aging. 2003;20:101-113.
70. Buttini M, Masliah E, Barbour R, et al. Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci. 2005;25:9096-9101.
71. Singh VK. Neuroautoimmunity: pathogenic implications for Alzheimer's disease. Gerontology. 1997;43:79-94.
72. Aarli JA. Role of cytokines in neurological disorders. Curr Med Chem. 2003;10:1931-1937.
73. Stamouli EC, Politis AM. Pro-inflammatory cytokines in Alzheimer's disease. Psychiatriki. 2016;27:264-275.
74. Hoffmann A, Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol Rev. 2006;210:171-186.
75. Yu F, Gong P, Hu Z, et al. Cu(II) enhances the effect of Alzheimer's amyloid-β peptide on microglial activation. J Neuroinflammation. 2015;12:122.
76. Filipov NM, Seegal RF, Lawrence DA. Manganese potentiates in vitro production of proinflammatory cytokines and nitric oxide by microglia through a nuclear factor kappa B-dependent mechanism. Toxicol Sci. 2005;84:139-148.
77. Town T, Nikolic V, Tan J. The microglial “activation” continuum: from innate to adaptive responses. J Neuroinflammation. 2005;2:24.
78. Mori T, Koyama N, Arendash GW, Horikoshi-Sakuraba Y, Tan J, Town T. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease. Glia. 2010;58:300-314
79. Zhang Y, Wu Y, Li W, et al. Ketamine inhibits lipopolysaccharide-induced astrocytes activation by suppressing TLR4/NF-κB pathway. Cell Physiol Biochem. 2012;30:609-617.
80. Frakes AE, Ferraiuolo L, Haidet-Phillips AM, et al. Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis. Neuron. 2014;81:1009-1023.
81. Walker-Caulfield ME, Guo Y, Johnson RK, et al. NFκB signaling drives pro-granulocytic astroglial responses to neuromyelitis optica patient IgG. J Neuroinflammation. 2015;12:185.
82. Jiang T, Cadenas E. Astrocytic metabolic and inflammatory changes as a function of age. Aging Cell. 2014;13:1059-1067.
83. Downen M, Amaral TD, Hua LL, Zhao ML, Lee SC. Neuronal death in cytokine-activated primary human brain cell culture: role of tumor necrosis factor-alpha. Glia. 1999;28:114-127.
84. Akama KT, Van Eldik LJ. Beta-amyloid stimulation of inducible nitric-oxide synthase in astrocytes is interleukin-1beta- and tumor necrosis factor-alpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor- and NFkappaB-inducing kinase-dependent signaling mech. J Biol Chem. 2000;275:7918-7924.
85. Wang P, Guan P-P, Wang T, Yu X, Guo J-J, Wang Z-Y. Aggravation of Alzheimer's disease due to the COX-2-mediated reciprocal regulation of IL-1β and Aβ between glial and neuron cells. Aging Cell. 2014;13:605-615.
86. Coelho-Santos V, Leitão RA, Cardoso FL, et al. The TNF-α/NF-κB signaling pathway has a key role in methamphetamine-induced blood-brain barrier dysfunction. J Cereb Blood Flow Metab. 2015;35:1260-1271.
87. Park R, Kook S-Y, Park J-C, Mook-Jung I. Aβ1-42 reduces P-glycoprotein in the blood-brain barrier through RAGE-NF-κB signaling. Cell Death Dis. 2014;5:e1299.
88. He F-Q, Qiu B-Y, Zhang X-H, et al. Tetrandrine attenuates spatial memory impairment and hippocampal neuroinflammation via inhibiting NF-κB activation in a rat model of Alzheimer's disease induced by amyloid-β(1-42). Brain Res. 2011;1384:89-96.
89. Medeiros R, Kitazawa M, Passos GF, et al. Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice. Am J Pathol. 2013;182:1780-1789.
90. Zeng Z, Xu J, Zheng W. Artemisinin protects PC12 cells against β-amyloid-induced apoptosis through activation of the ERK1/2 signaling pathway. Redox Biol. 2017;12:625-633.
91. Brambilla R, Morton PD, Ashbaugh JJ, Karmally S, Lambertsen KL, Bethea JR. Astrocytes play a key role in EAE pathophysiology by orchestrating in the CNS the inflammatory response of resident and peripheral immune cells and by suppressing remyelination. Glia. 2014;62:452-467.
92. McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett. 1987;79:195-200.
93. Huang Y, Erdmann N, Peng H, Zhao Y, Zheng J. The role of TNF related apoptosis-inducing ligand in neurodegenerative diseases. Cell Mol Immunol. 2005;2:113-122.
94. Jazvinšćak Jembrek M, Hof PR, Šimić G. Ceramides in Alzheimer's disease: key mediators of neuronal apoptosis induced by oxidative stress and Aβ accumulation. Oxid Med Cell Longev. 2015;2015:346783.
95. Baek S-S, Kim S-H. Treadmill exercise ameliorates symptoms of Alzheimer disease through suppressing microglial activation-induced apoptosis in rats. J Exerc Rehabil. 2016;12:526-534.
96. Singh AK, Bissoyi A, Kashyap MP, Patra PK, Rizvi SI. Autophagy activation alleviates amyloid-β-induced oxidative stress, apoptosis and neurotoxicity in human neuroblastoma SH-SY5Y cells. Neurotox Res. 2017;32:351-361.
97. Fossati S, Ghiso J, Rostagno A. Insights into caspase-mediated apoptotic pathways induced by amyloid-β in cerebral microvascular endothelial cells. Neurodegener Dis. 2012;10:324-328.
98. Picone P, Carrotta R, Montana G, Nobile MR, San Biagio PL, Di Carlo M. Abeta oligomers and fibrillar aggregates induce different apoptotic pathways in LAN5 neuroblastoma cell cultures. Biophys J. 2009;96:4200-4211.
99. Ono K, Condron MM, Teplow DB. Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc Natl Acad Sci U S A. 2009;106:14745-14750.
100. Fossati S, Cam J, Meyerson J, et al. Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloid-beta variants in cells composing the cerebral vessel walls. FASEB J. 2010;24:229-241.
101. He B, Zheng M, Liu Q, et al. Injected Amyloid beta in the olfactory bulb transfers to other brain regions via neural connections in mice. Mol Neurobiol. 2017. https://doi.org/10.1007/s12035-017-0446-1 [Epub ahead of print].
102. Kang Q, Xiang Y, Li D, et al. MiR-124-3p attenuates hyperphosphorylation of Tau protein-induced apoptosis via caveolin-1-PI3K/Akt/GSK3β pathway in N2a/APP695swe cells. Oncotarget. 2017;8:24314-24326.
103. Papuć E, Krupski W, Kurys-Denis E, Rejdak K. Antibodies against small heat-shock proteins in Alzheimer's disease as a part of natural human immune repertoire or activation of humoral response? J Neural Transm. 2016;123:455-461.
104. Bouras C, Riederer BM, Kövari E, Hof PR, Giannakopoulos P. Humoral immunity in brain aging and Alzheimer's disease. Brain Res Brain Res Rev. 2005;48:477-487.
105. D'Andrea MR. Add Alzheimer's disease to the list of autoimmune diseases. Med Hypotheses. 2005;64:458-463.
106. Piacentini R, Li Puma DD, Ripoli C, et al. Herpes Simplex Virus type-1 infection induces synaptic dysfunction in cultured cortical neurons via GSK-3 activation and intraneuronal amyloid-β protein accumulation. Sci Rep. 2015;5:15444.
107. Civitelli L, Marcocci ME, Celestino I, et al. Herpes simplex virus type 1 infection in neurons leads to production and nuclear localization of APP intracellular domain (AICD): implications for Alzheimer's disease pathogenesis. J Neurovirol. 2015;21:480-490.
108. Harris SA, Harris EA. Herpes simplex virus type 1 and other pathogens are key causative factors in sporadic Alzheimer's disease. J Alzheimers Dis. 2015;48:319-353.
109. Wozniak MA, Mee AP, Itzhaki RF. Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. J Pathol. 2009;217:131-138.
110. Wozniak MA, Frost AL, Itzhaki RF. Alzheimer's disease-specific tau phosphorylation is induced by herpes simplex virus type 1. J Alzheimers Dis. 2009;16:341-350.
111. Zambrano A, Solis L, Salvadores N, Cortés M, Lerchundi R, Otth C. Neuronal cytoskeletal dynamic modification and neurodegeneration induced by infection with herpes simplex virus type 1. J Alzheimers Dis. 2008;14:259-269.
112. Bonda DJ, Wang X, Perry G, et al. Oxidative stress in Alzheimer disease: a possibility for prevention. Neuropharmacology. 2010;59:290-294.
113. Moazed TC, Kuo CC, Grayston JT, Campbell LA. Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Infect Dis. 1998;177:1322-1325.
114. Itzhaki RF, Wozniak MA, Appelt DM, Balin BJ. Infiltration of the brain by pathogens causes Alzheimer's disease. Neurobiol Aging. 2004;25:619-627.
115. Contini C, Seraceni S, Cultrera R, Castellazzi M, Granieri E, Fainardi E. Chlamydophila pneumoniae Infection and Its Role in Neurological Disorders. Interdiscip Perspect Infect Dis. 2010;2010:273573.
116. Boelen E, Steinbusch HWM, Pronk I, et al. Inflammatory responses following Chlamydia pneumoniae infection of glial cells. Eur J Neurosci. 2007;25:753-760.
117. Gérard HC, Wildt KL, Whittum-Hudson JA, Lai Z, Ager J, Hudson AP. The load of Chlamydia pneumoniae in the Alzheimer's brain varies with APOE genotype. Microb Pathog. 2005;39:19-26.
118. Kaplan M, Yavuz SS, Cinar B, et al. Detection of Chlamydia pneumoniae and Helicobacter pylori in atherosclerotic plaques of carotid artery by polymerase chain reaction. Int J Infect Dis. 2006;10 2:116-123.
119. Gardener H, Caunca MR, Dong C, et al. Ultrasound markers of carotid atherosclerosis and cognition: the Northern Manhattan study. Stroke. 2017;48 7:1855-1861.
120. Lima LM, Carvalho MDG, Ferreira CN, et al. Atheromatosis extent in coronary artery disease is not correlated with apolipoprotein-E polymorphism and its plasma levels, but associated with cognitive decline. Curr Alzheimer Res. 2010;7 6:556-563.
121. Rusanen M, Kivipelto M, Levälahti E, et al. Heart diseases and long-term risk of dementia and Alzheimer's disease: a population-based CAIDE study. J Alzheimers Dis. 2014;42 1:183-191.
122. Al-Ghamdi A, Jiman-Fatani AA, El-Banna H. Role of Chlamydia pneumoniae, Helicobacter pylori and cytomegalovirus in coronary artery disease. Pak J Pharm Sci. 2011;24 2:95-101.
123. Roulis E, Bachmann NL, Myers GSA, et al. Comparative genomic analysis of human Chlamydia pneumoniae isolates from respiratory, brain and cardiac tissues. Genomics. 2015;106 6:373-383.
124. Lim C, Hammond CJ, Hingley ST, Balin BJ. Chlamydia pneumoniae infection of monocytes in vitro stimulates innate and adaptive immune responses relevant to those in Alzheimer's disease. J Neuroinflammation. 2014;11 1:217.
125. Arking EJ, Appelt DM, Abrams JT, Kolbe S, Hudson AP, Balin BJ. Ultrastructural analysis of chlamydia pneumoniae in the Alzheimer's brain. Pathogenesis (Amst). 1999;1 3:201-211.
126. Balin BJ, Gérard HC, Arking EJ, et al. Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Med Microbiol Immunol. 1998;187 1:23-42.
127. Gérard HC, Dreses-Werringloer U, Wildt KS, et al. Chlamydophila (Chlamydia) pneumoniae in the Alzheimer's brain. FEMS Immunol Med Microbiol. 2006;48 3:355-366.
128. Appelt DM, Roupas MR, Way DS, et al. Inhibition of apoptosis in neuronal cells infected with Chlamydophila (Chlamydia) pneumoniae. BMC Neurosci. 2008;9:13.
129. Little CS, Hammond CJ, MacIntyre A, Balin BJ, Appelt DM. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol Aging. 2004;25 4:419-429.
130. Miklossy J. Emerging roles of pathogens in Alzheimer disease. Expert Rev Mol Med. 2011;13:e30.
131. Riviere GR, Riviere KH, Smith KS. Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer's disease. Oral Microbiol Immunol. 2002;17:113-118.
132. Miklossy J, Khalili K, Gern L, et al. Borrelia burgdorferi persists in the brain in chronic lyme neuroborreliosis and may be associated with Alzheimer disease. J Alzheimers Dis 2004;6:639-649.
133. McManus RM, Higgins SC, Mills KHG, Lynch MA. Respiratory infection promotes T cell infiltration and amyloid-β deposition in APP/PS1 mice. Neurobiol Aging. 2014;35:109-121.
134. Kazakos EI, Kountouras J, Polyzos SA, Deretzi G. Novel aspects of defensins' involvement in virus-induced autoimmunity in the central nervous system. Med Hypotheses. 2017;102:33-36.
135. Hill JM, Clement C, Pogue AI, Bhattacharjee S, Zhao Y, Lukiw WJ. Pathogenic microbes, the microbiome, and Alzheimer's disease (AD). Front Aging Neurosci. 2014;6:1-5.
136. Blaser MJ. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis. 1990;161:626-633.
137. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH consensus development panel on helicobacter pylori in peptic ulcer disease. JAMA. 1994;272:65-69.
138. Kinoshita J. Pathogens as a cause of Alzheimer's disease. Neurobiol Aging. 2004;25:639-640.
139. Pace F, Bianchi Porro G. Gastro-oesophageal reflux and Helicobacter pylori. Ital J Gastroenterol Hepatol. 1998;30:S289-S293.
140. Kountouras J, Chatzopoulos D, Zavos C, et al. Helicobacter pylori infection might contribute to esophageal adenocarcinoma progress in subpopulations with gastroesophageal reflux disease and Barrett's esophagus. Helicobacter. 2012;17:402-403.
141. Kountouras J, Chatzopoulos D, Zavos C. Eradication of Helicobacter pylori might halt the progress to oesophageal adenocarcinoma in patients with gastro-oesophageal reflux disease and Barrett's oesophagus. Med Hypotheses. 2007;68:1174-1175.
142. Kountouras J, Zavos C, Chatzopoulos D, Katsinelos P. Helicobacter pylori and gastro-oesophageal reflux disease. Lancet (London, England). 2006;368:986; author reply 986-7.
143. Kountouras J, Zavos C, Polyzos SA, Katsinelos P. Helicobacter pylori infection and gastroesophageal reflux disease - Barrett's esophagus sequence “dilemma”. Ann Gastroenterol. 2015;28:153.
144. Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet (London, England). 2001;357:1738-1742.
145. Moayyedi P. Should we test for Helicobacter pylori before treating gastroesophageal reflux disease? Can J Gastroenterol. 2005;19:425-427.
146. Bahmanyar S, Zendehdel K, Nyrén O, Ye W. Risk of oesophageal cancer by histology among patients hospitalised for gastroduodenal ulcers. Gut. 2007;56:464-468.
147. Lee YY, Mahendra Raj S, Graham DY. Helicobacter pylori infection-a boon or a bane: lessons from studies in a low-prevalence population. Helicobacter. 2013;18:338-346.
148. Graham DY. Helicobacter pylori is not and never was “protective” against anything, including GERD. Dig Dis Sci. 2003;48:629-630.
149. Zagari RM, Romano M, Ojetti V, et al. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. Dig Liver Dis. 2015;47:903-912.
150. Kountouras J, Deretzi G, Zavos C, et al. Association between Helicobacter pylori infection and acute inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2005;12:139-143.
151. Mendall MA, Goggin PM, Molineaux N, et al. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J. 1994;71:437-439.
152. McColl KE. What remaining questions regarding Helicobacter pylori and associated diseases should be addressed by future research? View from Europe Gastroenterology. 1997;113(6 Suppl):S158-S162.
153. Kountouras J, Mylopoulos N, Chatzopoulos D, et al. Eradication of Helicobacter pylori may be beneficial in the management of chronic open-angle glaucoma. Arch Intern Med. 2002;162:1237-1244.
154. Xu Q, Schett G, Perschinka H, et al. Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation. 2000;102:14-20.
155. Sawayama Y, Ariyama I, Hamada M, et al. Association between chronic Helicobacter pylori infection and acute ischemic stroke: Fukuoka Harasanshin Atherosclerosis Trial (FHAT). Atherosclerosis. 2005;178 2:303-309.
156. Pugazhenthi S. Metabolic syndrome and the cellular phase of Alzheimer's disease. Prog Mol Biol Transl Sci. 2017;146:243-258.
157. Craft S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord. 2006;20 4:298-301.
158. Wardlaw JM, Sandercock PAG, Dennis MS, Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke. 2003;34 3:806-812.
159. Mecocci P, Parnetti L, Reboldi GP, et al. Blood-brain-barrier in a geriatric population: barrier function in degenerative and vascular dementias. Acta Neurol Scand. 1991;84 3:210-213.
160. Hofman A, Ott A, Breteler MM, et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet (London, England). 1997;349 9046:151-154.
161. de la Torre JC, Stefano GB. Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide. Brain Res Brain Res Rev. 2000;34 3:119-136.
162. Ascher-Svanum H, Chen Y-F, Hake A, et al. Cognitive and functional decline in patients with mild Alzheimer dementia with or without comorbid diabetes. Clin Ther. 2015;37 6:1195-1205.
163. Pasquier F, Leys D. Why are stroke patients prone to develop dementia? J Neurol. 1997;244 3:135-142.
164. Enarsson K, Brisslert M, Backert S, Quiding-Järbrink M. Helicobacter pylori induces transendothelial migration of activated memory T cells. Infect Immun. 2005;73 2:761-769.
165. D'Elios MM, Amedei A, Benagiano M, Azzurri A, Del Prete G. Helicobacter pylori, T cells and cytokines: the “dangerous liaisons”. FEMS Immunol Med Microbiol. 2005;44 2:113-119.
166. Hafsi N, Voland P, Schwendy S, et al. Human dendritic cells respond to Helicobacter pylori, promoting NK cell and Th1-effector responses in vitro. J Immunol. 2004;173 2:1249-1257.
167. Kranzer K, Söllner L, Aigner M, et al. Impact of Helicobacter pylori virulence factors and compounds on activation and maturation of human dendritic cells. Infect Immun. 2005;73 7:4180-4189.
168. Rathinavelu S, Kao JY, Zavros Y, Merchant JL. Helicobacter pylori outer membrane protein 18 (Hp1125) induces dendritic cell maturation and function. Helicobacter. 2005;10 5:424-432.
169. Voland P, Hafsi N, Zeitner M, Laforsch S, Wagner H, Prinz C. Antigenic properties of HpaA and Omp18, two outer membrane proteins of Helicobacter pylori. Infect Immun. 2003;71 7:3837-3843.
170. Tsai H-F, Hsu P-N. Interplay between Helicobacter pylori and immune cells in immune pathogenesis of gastric inflammation and mucosal pathology. Cell Mol Immunol. 2010;7 4:255-259.
171. Neu B, Puschmann AJ, Mayerhofer A, et al. TNF-alpha induces apoptosis of parietal cells. BiochemPharmacol. 2003;65 10:1755-1760.
172. Bussiere FI, Chaturvedi R, Asim M, et al. Low multiplicity of infection of Helicobacter pylori suppresses apoptosis of B lymphocytes. Cancer Res. 2006;66 13:6834-6842.
173. Watanabe S, Takagi A, Koga Y, Kamiya S, Miwa T. Helicobacter pylori induces apoptosis in gastric epithelial cells through inducible nitric oxide. J Gastroenterol Hepatol. 2000;15 2:168-174.
174. Potthoff A, Ledig S, Martin J, et al. Significance of the caspase family in Helicobacter pylori induced gastric epithelial apoptosis. Helicobacter. 2002;7 6:367-377.
175. Maeda S, Yoshida H, Mitsuno Y, et al. Analysis of apoptotic and antiapoptotic signalling pathways induced by Helicobacter pylori. Gut. 2002;50 6:771-778.
176. Liu HF, Liu WW, Wang GA, Teng XC. Effect of Helicobacter pylori infection on Bax protein expression in patients with gastric precancerous lesions. World J Gastroenterol. 2005;11 37:5899-5901.
177. Yamasaki E, Wada A, Kumatori A, et al. Helicobacter pylori vacuolating cytotoxin induces activation of the proapoptotic proteins Bax and Bak, leading to cytochrome c release and cell death, independent of vacuolation. J Biol Chem. 2006;281 16:11250-11259.
178. Fernández-Vizarra P, Fernández AP, Castro-Blanco S, et al. Expression of nitric oxide system in clinically evaluated cases of Alzheimer's disease. Neurobiol Dis. 2004;15 2:287-305.
179. Balez R, Ooi L. Getting to NO Alzheimer's disease: Neuroprotection versus neurotoxicity mediated by nitric oxide. Oxid Med Cell Longev. 2016;2016:1-8.
180. Tezel G, Wax MB. The mechanisms of hsp27 antibody-mediated apoptosis in retinal neuronal cells. J Neurosci. 2000;20 10:3552-3562.
181. Vorobjova T, Faller G, Maaroos HI, et al. Significant increase in antigastric autoantibodies in a long-term follow-up study of H. pylori gastritis. Virchows Arch. 2000;437 1:37-45.
182. Negrini R, Savio A, Poiesi C, et al. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology. 1996;111 3:655-665.
183. Sheu BS, Shiesh SC, Yang HB, Su IJ, Chen CY, Lin XZ. Implications of Helicobacter pylori serological titer for the histological severity of antral gastritis. Endoscopy. 1997;29 1:27-30.
184. Veijola LI, Oksanen AM, Sipponen PI, Rautelin HIK. Association of autoimmune type atrophic corpus gastritis with Helicobacter pylori infection. World J Gastroenterol. 2010;16 1:83-88.
185. Moran AP, Prendergast MM. Molecular mimicry in Campylobacter jejuni and Helicobacter pylori lipopolysaccharides: contribution of gastrointestinal infections to autoimmunity. J Autoimmun. 2001;16 3:241-256.
186. Chiba S, Sugiyama T, Matsumoto H, et al. Antibodies against Helicobacter pylori were detected in the cerebrospinal fluid obtained from patients with Guillain-Barré syndrome. Ann Neurol. 1998;44 4:686-688.
187. Chiba S, Sugiyama T, Yonekura K, et al. An antibody to VacA of Helicobacter pylori in cerebrospinal fluid from patients with Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry. 2002;73 1:76-78.
188. Kountouras J, Deretzi G, Grigoriadis N, et al. Guillain-Barré syndrome. Lancet Neurol. 2008;7 12:1080-1081-5.
189. Kountouras J, Mylopoulos N, Konstas AGP, Zavos C, Chatzopoulos D, Boukla A. Increased levels of Helicobacter pylori IgG antibodies in aqueous humor of patients with primary open-angle and exfoliation glaucoma. Graefe's Arch Clin Exp Ophthalmol. 2003;241 11:884-890.
190. Zelaya MV, Pérez-Valderrama E, de Morentin XM, et al. Olfactory bulb proteome dynamics during the progression of sporadic Alzheimer's disease: identification of common and distinct olfactory targets across Alzheimer-related co-pathologies. Oncotarget. 2015;6 37:39437-39456.
191. Attems J, Walker L, Jellinger KA. Olfactory bulb involvement in neurodegenerative diseases. Acta Neuropathol. 2014;127 4:459-475.
192. Devanand DP. Olfactory identification deficits, cognitive decline, and dementia in older adults. Am J Geriatr Psychiatry. 2016;24 12:1151-1157.
193. Masurkar AV, Devanand DP. Olfactory dysfunction in the elderly: basic circuitry and alterations with normal aging and Alzheimer's disease. Curr Geriatr Reports. 2014;3 2:91-100.
194. Kovács T, Cairns NJ, Lantos PL. Olfactory centres in Alzheimer's disease: olfactory bulb is involved in early Braak's stages. NeuroReport. 2001;12 2:285-288.
195. Arnold SE, Lee EB, Moberg PJ, et al. Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in Alzheimer disease. Ann Neurol. 2010;67 4:462-469.
196. Thomann PA, Dos Santos V, Seidl U, Toro P, Essig M, Schröder J. MRI-derived atrophy of the olfactory bulb and tract in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis. 2009;17 1:213-221.
197. Förster S, Vaitl A, Teipel SJ, et al. Functional representation of olfactory impairment in early Alzheimer's disease. J Alzheimers Dis. 2010;22 2:581-591.
198. Payão SLM, Rasmussen LT. Helicobacter pylori and its reservoirs: A correlation with the gastric infection. World J Gastrointest Pharmacol Ther. 2016;7 1:126-132.
199. Souto R, Colombo APV. Detection of Helicobacter pylori by polymerase chain reaction in the subgingival biofilm and saliva of non-dyspeptic periodontal patients. J Periodontol. 2008;79 1:97-103.
200. Amiri N, Abiri R, Eyvazi M, Zolfaghari MR, Alvandi A. The frequency of Helicobacter pylori in dental plaque is possibly underestimated. Arch Oral Biol. 2015;60 5:782-788.
201. Ahmed KS, Khan AA, Ahmed I, et al. Prevalence study to elucidate the transmission pathways of Helicobacter pylori at oral and gastroduodenal sites of a South Indian population. Singapore Med J. 2006;47 4:291-296.
202. Silva DG, Stevens RH, Macedo JMB, et al. Detection of cytotoxin genotypes of Helicobacter pylori in stomach, saliva and dental plaque. Arch Oral Biol. 2009;54 7:684-688.
203. Kazanowska-Dygdała M, Duś I, Radwan-Oczko M. The presence of Helicobacter pylori in oral cavities of patients with leukoplakia and oral lichen planus. J Appl Oral Sci. 2016;24 1:18-23.
204. Batioglu-Karaaltin A, Saatci O, Akpinar M, et al. Helicobacter pylori in lacrimal secretions. Ear Nose Throat J. 2016;95 3:E8-E11.
205. Miklossy J, McGeer PL. Common mechanisms involved in Alzheimer's disease and type 2 diabetes: a key role of chronic bacterial infection and inflammation. Aging (Albany NY). 2016;8 4:575-588.
206. Kountouras J, Zavos C, Katsinelos P, Vardaka E. Glaucoma and Helicobacter pylori: eyes “wide open”!. Dig Liver Dis. 2012;44 11:962-963; author reply 963.
207. Rasoulinejad SA, Kasiri A, Montazeri M, et al. The association between primary open angle glaucoma and clustered components of metabolic syndrome. Open Ophthalmol J. 2015;9:149-155.
208. Deretzi G, Kountouras J, Polyzos SA, et al. Gastrointestinal immune system and brain dialogue implicated in neuroinflammatory and neurodegenerative diseases. Curr Mol Med. 2011;11 8:696-707.
209. Kountouras J, Zavos C, Polyzos SA, Deretzi G. The gut-brain axis: Interactions between Helicobacter pylori and enteric and central nervous systems. Ann Gastroenterol. 2015;28 4:506.
210. Kountouras J. Helicobacter pylori: an intruder involved in conspiring glaucomatous neuropathy. Br J Ophthalmol. 2009;93 11:1413-1415.
211. Izzotti A, Saccà SC, Bagnis A, Recupero SM. Glaucoma and Helicobacter pylori infection: correlations and controversies. Br J Ophthalmol. 2009;93 11:1420-1427.
212. Yun C-H, Lee H-Y, Lee SK, et al. Amyloid burden in obstructive sleep apnea. J Alzheimers Dis. 2017;59 1:21-29.
213. Sugimoto M, Yamaoka Y. Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy. Arch Immunol Ther Exp (Warsz). 2009;57 1:45-56.
214. Perri F, Clemente R, Festa V, et al. Serum tumour necrosis factor-alpha is increased in patients with Helicobacter pylori infection and CagA antibodies. Ital J Gastroenterol Hepatol. 1999;31 4:290-294.
215. Kountouras J, Zavos C, Zeglinas C, Polyzos SA, Katsinelos P. Helicobacter pylori -related impact on glaucoma pathophysiology. Invest Ophthalmol Vis Sci. 2015;56 13:8029-8030.
216. Kountouras J, Polyzos SA, Gavalas E, et al. A potential impact of Helicobacter pylori infection on minimal hepatic encephalopathy pathobiology. J Gastrointestin Liver Dis. 2016;25 3:405-406.
217. Izzotti A, Durando P, Ansaldi F, Gianiorio F, Pulliero A. Interaction between Helicobacter pylori, diet, and genetic polymorphisms as related to non-cancer diseases. Mutat Res. 2009;667 1-2:142-157.
218. Beydoun MA, Beydoun HA, Shroff MR, Kitner-Triolo MH, Zonderman AB. Helicobacter pylori Seropositivity and cognitive performance among US adults. Psychosom Med. 2013;75 5:486-496.
219. Dando SJ, Mackay-Sim A, Norton R, et al. Pathogens penetrating the central nervous system: infection pathways and the cellular and molecular mechanisms of invasion. Clin Microbiol Rev. 2014;27 4:691-726.
220. Shima K, Kuhlenbäumer G, Rupp J. Chlamydia pneumoniae infection and Alzheimer's disease: a connection to remember? Med Microbiol Immunol. 2010;199 4:283-289.
221. Di Pietro M, Filardo S, Cazzavillan S, et al. Could past Chlamydial vascular infection promote the dissemination of Chlamydia pneumoniae to the brain? J Biol Regul Homeost Agents. 2015;27 1:155-164.
222. Kountouras J, Deretzi G, Zavos C, et al. Helicobacter pylori infection may trigger Guillain-Barré syndrome, Fisher syndrome and Bickerstaff brainstem encephalitis. J Neurol Sci. 2011;305 1-2:167-168; author reply 169.
223. Skaper SD. Mast Cell - Glia dialogue in chronic pain and neuropathic pain: blood-brain barrier implications. CNS Neurol Disord Drug Targets. 2016;15 9:1072-1078.
224. Kountouras J, Tsolaki M, Boziki M, et al. Association between Helicobacter pylori infection and mild cognitive impairment. Eur J Neurol. 2007;14 9:976-982.
225. Kountouras J, Tsolaki M, Gavalas E, et al. Relationship between Helicobacter pylori infection and Alzheimer disease. Neurology. 2006;66 6:938-940.
226. Smith AD, Refsum H. Homocysteine, B vitamins, and cognitive impairment. Annu Rev Nutr. 2016;36 1:211-239.
227. Fan G-Q, Qin R-R, Li Y-H, et al. Endothelial cells microparticle-associated protein disulfide isomerase promotes platelet activation in metabolic syndrome. Oncotarget. 2016;7 50:83231-83240.
228. Sreckovic B, Sreckovic VD, Soldatovic I, et al. Homocysteine is a marker for metabolic syndrome and atherosclerosis. Diabetes Metab Syndr. 2016; 11:179-182.
229. Kountouras J, Zavos C, Chatzopoulos D. Induction of apoptosis as a proposed pathophysiological link between glaucoma and Helicobacter pylori infection. Med Hypotheses. 2004;62 3:378-381.
230. Kountouras J, Mylopoulos N, Boura P, et al. Relationship between Helicobacter pylori infection and glaucoma. Ophthalmology. 2001;108 3:599-604.
231. Roubaud Baudron C, Letenneur L, Langlais A, et al. Does Helicobacter pylori infection increase incidence of dementia? The Personnes Agées QUID Study. J Am Geriatr Soc. 2013;61 1:74-78.
232. Katan M, Moon YP, Paik MC, Sacco RL, Wright CB, Elkind MSV. Infectious burden and cognitive function: the Northern Manhattan Study. Neurology. 2013;80 13:1209-1215.
233. Gale SD, Erickson LD, Brown BL, Hedges DW. Interaction between Helicobacter pylori and latent toxoplasmosis and demographic variables on cognitive function in young to middle-aged adults. PLoS ONE. 2015;10 1:1-18.
234. Malaguarnera M, Bella R, Alagona G, Ferri R, Carnemolla A, Pennisi G. Helicobacter pylori and Alzheimer's disease: a possible link. Eur J Intern Med. 2004;15 6:381-386.
235. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346 7:476-483.
236. Redéen S, Ryberg A, Petersson F, Eriksson O, Nägga K, Borch K. Homocysteine levels in chronic gastritis and other conditions: relations to incident cardiovascular disease and dementia. Dig Dis Sci. 2010;55 2:351-358.
237. Kountouras J, Polyzos SA, Grigoriadis N, Deretzi G. Helicobacter pylori -related vitamin B12 deficiency: a potential contributor in neuropsychiatric disorders. Indian J Psychol Med. 2015;37 4:475-476.
238. Zavos C, Kountouras J, Sakkias G, Venizelos I, Deretzi G, Arapoglou S. Histological presence of Helicobacter pylori bacteria in the trabeculum and iris of patients with primary open-angle glaucoma. Ophthalmic Res. 2012;47 3:150-156.
239. Kountouras J, Tsolaki F, Tsolaki M, et al. Helicobacter pylori -related ApoE 4 polymorphism may be associated with dysphagic symptoms in older adults. Dis Esophagus Off J Int Soc Dis Esophagus. 2016;29 7:842.
240. Ge R, Sun X. The in vivo functions of a histidine-rich protein Hpn in Helicobacter pylori: linking gastric and Alzheimer's diseases together? Med Hypotheses. 2011;77 5:788-790.
241. Xu Y, Wang Q, Liu Y, Cui R, Zhao Y. Is Helicobacter pylori infection a critical risk factor for vascular dementia? Int J Neurosci. 2016;126 10:899-903.
242. Wang X-L, Zeng J, Feng J, et al. Helicobacter pylori filtrate impairs spatial learning and memory in rats and increases β-amyloid by enhancing expression of presenilin-2. Front Aging Neurosci. 2014;6 APR:66.
243. Baudron CR, Chambonnier L, Buissionnière A, et al. An eighteen-month helicobacter infection does not induce amyloid plaques or neuroinflammation in brains of wild type C57BL/6J mice. J Alzheimers Dis. 2015;45 4:1045-1050.
244. Shiota S, Murakami K, Yoshiiwa A, et al. The relationship between Helicobacter pylori infection and Alzheimer's disease in Japan. J Neurol. 2011;258 8:1460-1463.
245. Huang W-S, Yang T-Y, Shen W-C, Lin C-L, Lin M-C, Kao C-H. Association between Helicobacter pylori infection and dementia. J Clin Neurosci. 2014;21 8:1355-1358.
246. Chang YP, Chiu GF, Kuo FC, et al. Eradication of Helicobacter pylori is associated with the progression of dementia: A population-based study. Gastroenterol Res Pract. 2013;2013:175729.
247. Berrett AN, Gale SD, Erickson LD, Brown BL, Hedges DW. Folate and inflammatory markers moderate the association between Helicobacter pylori exposure and cognitive function in US adults. Helicobacter. 2016;21 6:471-480.
248. Beydoun MA, Dore GA, Canas JA, Beydoun HA, Zonderman AB. Helicobacter pylori seropositivity's association with markers of iron, 1-carbon metabolism, and antioxidant status among US adults: A structural equations modeling approach. PLoS ONE. 2015;10 3:1-16.
249. Hu Y, Zhu Y, Lu N-H. Novel and effective therapeutic regimens for Helicobacter pylori in an era of increasing antibiotic resistance. Front Cell Infect Microbiol. 2017;7:168.
250. Alba C, Blanco A, Alarcón T. Antibiotic resistance in Helicobacter pylori. Curr Opin Infect Dis. 2017;30 5:489-497.
251. Kuo Y-T, Liou J-M, El-Omar EM, et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2 10:707-715.
252. Graham DY. Roadmap for elimination of gastric cancer in Korea. Korean J Intern Med. 2015;30 2:133-139.
253. Kazakos EI, Dorrell N, Polyzos SA, Deretzi G, Kountouras J. Comment on “Effect of biofilm formation by clinical isolates of Helicobacter pylori on the efflux-mediated resistance to commonly used antibiotics”. World J Gastroenterol. 2017;23 33:6194-6196.
254. Felice C, Federico C, Andrea F, et al. The hypothesis that Helicobacter pylori predisposes to Alzheimer's disease is biologically plausible. Sci Rep. 2017;7 1:7817.
255. Rovelet-Lecrux A, Legallic S, Wallon D, et al. A genome-wide study reveals rare CNVs exclusive to extreme phenotypes of Alzheimer disease. Eur J Hum Genet. 2012;20 6:613-617.